Opus Genetics Completes Enrollment in Phase 3 Gene Therapy Trial for Rare Blindness Disorder
MT Newswires Live
Aug 03
Opus Genetics (IRD) completed enrollment in its phase 3 registrational trial evaluating OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease, a rare condition that can cause blindness, the company said on Monday.
The trial was developed in collaboration with the US FDA and could support a future Biologics License Application.
Opus expects to begin dosing patients in Q4 and report topline data by the end of 2027. OPGx-LCA5 has received FDA Rare Pediatric Disease, Orphan Drug and RMAT designations, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.